Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. Latest Deal Amount. Sirtris Pharmaceuticals (NASDAQ:SIRT) ... as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in … [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … Description. Sirtris PharmaceuticalsGeneral Information. Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { M&A. $376M. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … //-->. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. And Sirtris says it is close to launching clinical trials for experimental drugs that could prove to be up to 1,000 times more potent. GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: Sirtris The proposed acquisition of Sirtris Pharmaceuticals (SIRT) is essentially aneffort to bolster GlaxoSmithKline's (NYSE:GSK)s pipeline in the Type 2 diabetes treatmentarea. Company profile page for Sirtris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. document.write("
Click here to add this page to your favorites"); Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … Action Alerts PLUS is a registered trademark of TheStreet, Inc. Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. CEO Christoph Westphal and the management team will continue to lead the unit. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. weekly.TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. Find the latest Genocea Biosciences, Inc. (GNCA) stock quote, history, news and other vital information to help you with your stock trading and investing. Sirtris founder and CEO Christoph Westphal will remain head of the unit once the cash sale of about $22.50 per share closes later this year. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23.